Sous-titre
CELANIRE Sylvain
Contenu
Body
Project status: active
Discovered by start-up Pragma Therapeutics, molecule PGT293, administered orally, significantly reduces hearing loss in mice exposed to acoustic trauma.
Led by Sylvain Celanire, CEO of Pragma Therapeutics, and his team, this project aims to determine the effective dosage and duration for the treatment, and when to start it in humans.
Sylvain Celanire
Chief Executive Officer
Pragma Therapeutics, Archamps, France